Biocytogen to Host 1-on-1 Meetings at BIO-EUROPE SPRING® 2023
March 15, 2023
Biocytogen’s antibody BD and licensing team is pleased to attend and host 1-on-1 meetings at the 17th annual BIO-Europe Spring, taking place March 20–22, 2023 in Basel, Switzerland. With the successful launch of Biocytogen’s proprietary fully human antibody mice (RenMabTM, RenLite® and RenNano®), Biocytogen has developed 6 fully human antibody discovery platforms for development of […]
Festival of Biologics – USA
March 10, 2023
Join us at the The Festival of Biologics USA in San Diego, CA from March 20- 22! Learn more about our antibody discovery capabilities and humanized antibody mice. Our Beacon- and FACS-based screening services can identify hundreds, or even thousands, of single B cells that generate antibodies to your target in one day, so let […]
Biocytogen Announces RenLite® Licensing Agreement with Janssen
March 8, 2023
BEIJING, March 8, 2023 — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Jonson & Johnson (“Janssen”). Under the agreement, Biocytogen grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen’s proprietary RenLite® […]
7th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference
March 2, 2023
Join us at the 7th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference in in London, UK from March 9-10, 2023! Whether you need humanized models, PK/PD services, or antibody discovery services, we’d love to partner with you to evaluate your novel immunotherapies. We have extensive experience testing novel monoclonal antibodies, bispecific antibodies, and cell-based therapies in […]
Biocytogen to Highlight Bispecific ADC Pipeline at World ADC London 2023
March 1, 2023
Biocytogen is excited to attend and deliver oral and poster presentations at the upcoming 13th World ADC London conference, held on March 13th-16th, 2023. Dr. W. Frank An, Senior Director of Antibody Therapeutics, will give an oral presentation entitled “Bispecific Antibody Drug Conjugates (BsADCs) Improve Anti-Tumor Efficacy in Preclinical Studies”. In the talk, Dr. An […]
Biocytogen’s Subsidiary Eucure Biopharma and Chipscreen Biosciences’ Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for Bispecific Antibody YH008
February 27, 2023
BEIJING, China, February 27, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced that its wholly owned subsidiary, Eucure (Beijing) Biopharma Co., Ltd. (“Eucure Biopharma”), has reached an exclusive licensing agreement with Chipscreen NewWay Biosciences (“Chipscreen NewWay”), a holding subsidiary of Shenzhen Chipscreen Biosciences Co., Ltd. (“Chipscreen Biosciences”, SSE: 688321) for the […]
Biocytogen Launches “Nano 100 Project” to Develop Fully Human Nanobody Therapeutics for Over 100 Targets
February 21, 2023
BEIJING, China, February 21, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced the launch of the “Nano 100 Project”, which aims to develop fully human nanobody drugs for over 100 targets. The Project combines Biocytogen’s proprietary fully human nanobody mouse, RenNano®, with its high-throughput in vitro and in vivo antibody screening […]
Webinar: Inflammatory Disease Modeling for Preclinical Studies
January 24, 2023
Our webinar “Inflammatory Disease Modeling for Preclinical Studies” was live at 1:00 PM EST on February 15th, 2023. In this webinar, we Provided a brief overview on molecular mechanisms driving disease progression. Discussed modeling inflammatory diseases in wild-type and humanized mice, including psoriasis, atopic dermatitis, delayed type hypersensitivity, inflammatory bowel disease and experimental autoimmune encephalomyelitis. Evaluated […]
PepTalk 2023
January 5, 2023
Join us at booth #401 at PepTalk 2023 from January 16-20 in San Diego, CA! Whether you need humanized models, PK/PD services, or antibody discovery services, we’d love to partner with you to evaluate your novel immunotherapies. We have extensive experience testing novel monoclonal antibodies, bispecific antibodies, and cell-based therapies in our highly specialized models. […]
Biocytogen and Hansoh Pharma Announce an Antibody License Agreement
January 3, 2023
BEIJING, China, and Shanghai, China, January 3, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SEHK : 02315) a clinical-stage biotechnology company with a focus on the antibody discovery and development based on its proprietary RenMiceTM HiTS Platforms and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”, SEHK: 3692), a leading innovation-driven pharmaceutical company with a […]
